Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Haematologica|March 30, 2019
Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXLPierre-Yves Dumas, Cécile Naudin, Séverine Martin-Lannerée, et al.
European Journal of Haematology|March 18, 2021
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional statusClaire Jouzier, Jean-François Hamel, Pierre-Yves Dumas, et al.
Blood Advances|May 24, 2024
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemiaAnne-Charlotte Le Floch, Florence Orlanducci, Marie-Christine Béné, et al.
Cancer Medicine|August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysisStéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Open Forum Infectious Diseases|March 12, 2025
Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry StudyXavier Brousse, Nicolas Rasandisona, Emilie Bérard, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Aline Renneville, Xavier Thomas, et al.
Leukemia Research|January 16, 2017
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFALining Wang, Emmanuel Raffoux, Xavier Thomas, et al.
Blood Cancer Journal|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry studyCamille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Pageof 15